Company News

As 2026 begins, bioMérieux proudly continues our tradition of looking into the next twelve months and analyzing how key food safety trends will influence the food supply chain and our partners’ operations. The three identified trends for 2026 will continue to develop and inform food safety and quality standards — standards that we at bioMérieux are proud to help pioneer and contribute to.

bioMérieux confirms its ethical commitment to clinical research through a Bioethics Charter that guarantees transparency, accountability, and respect for human dignity. In particular, it aims to protect research participants when collecting and using biological samples and personal data.

bioMérieux reaffirmed its role as the global leader in infectious disease diagnostics and antimicrobial resistance (AMR) advocacy at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo.

bioMérieux has a long history of collaboration with Moderna, a biotechnology company that gained worldwide recognition during the COVID-19 pandemic for its rapid development of a mRNA-based vaccine. Today, this collaboration is helping accelerate the development of individualized cancer treatments.

bioMérieux is partnering with AdventHealth Orlando as they become the first institution to adopt the VITEK® REVEAL™ Fast Antimicrobial Susceptibility Testing (AST) System for clinical use in the United States.